�The U.S. Food and Drug Administration is warning consumers wHO filled prescriptions at The Medicine Shoppe pharmacies situated at 8035A Liberty Road and 5900 Reisterstown Road in Baltimore that they may have received drugs that were either expired or suspected counterfeit. The FDA is particularly interested because a number of the drugs are for serious diseases and could have an adverse effect on treatment.
The products in question include:
-- Lisinopril (20 milligrams)
-- Guaifenesin/Dextromethorphan (600 mg and 1000 mg)
-- Gabapentin (century mg, ccc mg and 400 mg)
-- Metoprolol (50 mg)
-- Nifedipine (30 mg)
-- Diclofenac Sodium (30 mg)
-- Glucophage (D mg Extended Release)
-- Glucovance (125 mg and five hundred mg)
-- Glipizide/Metformin (2.50 mg/250 mg)
-- Furosemide (20 mg)
-- Tamoxifen Citrate (10 mg)
-- Metformin HCl ER (500 mg)
-- Calcitrol (0.25 micrograms)
The FDA has no evidence that any other Medicine Shoppe pharmacies remote of the 8035A Liberty Road and 5900 Reisterstown Road facilities are involved.
Because the safety and efficacy of the listed drugs has not been established, the FDA is strongly advising consumers world Health Organization filled prescriptions for these drugs at these two pharmacies to contact their prescribing physician immediately for new prescriptions. Additionally, consumers in possession of the above listed prescription drugs from these pharmacies should call FDA at 800-521-5783 for further information on how to dispose of the drugs.
Consumers and health care professionals can report contrary events to the FDA's MedWatch program at 800-FDA-1088, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, Md 20852-9787, or online at www.fda.gov/medwatch/report.htm.
More info
Friday, 22 August 2008
Tuesday, 12 August 2008
Acid - Various Artists
Artist: Acid - Various Artists
Genre(s):
Other
Discography:
Tamagochi Band - Acid Jazz vs. Drum.n.Bass vol 1
Year:
Tracks: 11
Skinfarm - Acid Jazz vs. Drum.n.Bass vol 1
Year:
Tracks: 11
Roo-Kaan - Acid Jazz vs. Drum.n.Bass vol 1
Year:
Tracks: 11
R-Kanzas - Acid Jazz vs. Drum.n.Bass vol 1
Year:
Tracks: 11
KAI TRACID - 100% Trance
Year:
Tracks: 19
GroovGroopies - Acid Jazz vs. Drum.n.Bass vol 1
Year:
Tracks: 11
F-Frank - Acid Jazz vs. Drum.n.Bass vol 1
Year:
Tracks: 11
Droom-Boom - Acid Jazz vs. Drum.n.Bass vol 1
Year:
Tracks: 11
DJ Quit - Acid Jazz vs. Drum.n.Bass vol 1
Year:
Tracks: 11
DJ Lu-na - Acid Jazz vs. Drum.n.Bass vol 1
Year:
Tracks: 11
Bass-Tard - Acid Jazz vs. Drum.n.Bass vol 1
Year:
Tracks: 11
Ash-Hole - Acid Jazz vs. Drum.n.Bass vol 1
Year:
Tracks: 11
Wednesday, 6 August 2008
Soft Drinks And Fruit Drinks And Risk For Diabetes In African-American Women Linked By Study
�Researchers from Boston University's Slone Epidemiology Center take found that regular consumption of sugar-sweetened soft drinks and fruit drinks is associated with an increased risk for type 2 diabetes in African-American women. These findings appear in the July 28
Oncologists Not Providing Enough Information About Palliative Care
�
According to a study published on bmj.com, most
genus Cancer patients make a decision about treatment with small or no
information about the endurance benefits of palliative chemotherapy.
Palliative chemotherapy is a way to boil down the austereness of symptoms for
patients with advanced cancer. Though it is not designed to cure the
crab, the therapy has meek survival gains, of months rather than
years, for patients in advanced stages of malignant neoplastic disease. In the UK, it is
expected that doctors provide accurate information to patients so an
informed decision can be made before initiating chemotherapy.
Researchers from the University of Bristol, however, have found that
over 66% of genus Cancer patients remained uninformed and did not receive
information about the survival benefits of palliative chemotherapy.
They assessed the cases of 37 patients - with colorectal, non-small
cell lung, or pancreatic cancer - at a big teaching infirmary or a
district general hospital in the south west of England. All of the
patients had advanced cancer, and permitted digital recording of their
consultations with oncologists. In order to analyze how survival put on
was discussed when patients were offered palliative chemotherapy, the
researchers utilized data from ASPECTS - a study of patients' of
experiences treatments. Before the patient met with the oncologist, a
researcher interviewed the patient. The researcher then recorded the
consultation with the health professional and followed-up one more than time
with the patient role within the following weeks.
The investigators found that physicians were consistent in informing
patients that they were past the point of a cure and one was not being
sought for them. However, there was considerable variance in how much
information about survival benefits from palliative chemotherapy was
tending. Some
patients received numerical data ("about little Joe weeks") while other
standard an idea of timescale ("a few months extra"), vague references
("buy you some time"), or nix at all. Of the 37 patients, six were
provided with numerical information about the treatment's survival gains. Most
of the consultations, 26 of 37, resulted in a vague discussion of
natural selection benefits or in no discussion at all.
It is possible, according to the researchers, that the "intrusiveness
of unfavorable numbers," such as the turn of months or weeks left to
live, undermines a doctor's relationship with her patient and
engenders a negative state. "Giving comprehensible and appropriate
information about survival benefit is extremely difficult. In addition,
the hesitancy to inform patients of the limited survival advance of
alleviator chemotherapy may be motivated by a desire to 'protect'
patients from tough news," write the authors. "However, the reluctance to
address these difficulties and sensitivities may be hampering patients'
power to make informed decisions about their future treatment."
The researchers intimate that oncologists and genus Cancer teams should
sensitively communicate enough data that can help a patient construct
an informed, realistic decision. In addition, they advocate training
for oncologists to help them better pass along survival information to
patients.
What oncologists tell patients about endurance benefits of
palliative chemotherapy and implications for informed consent:
qualitative study
Suzanne Audrey, Julian Abel, Jane M Blazeby, Stephen Falk,
Rona Campbell
BMJ (2008). 337: a752.
doi:10.1136/bmj.a752
Click
Here to View Journal Web Site
Written by: Peter M Crosta
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More info
According to a study published on bmj.com, most
genus Cancer patients make a decision about treatment with small or no
information about the endurance benefits of palliative chemotherapy.
Palliative chemotherapy is a way to boil down the austereness of symptoms for
patients with advanced cancer. Though it is not designed to cure the
crab, the therapy has meek survival gains, of months rather than
years, for patients in advanced stages of malignant neoplastic disease. In the UK, it is
expected that doctors provide accurate information to patients so an
informed decision can be made before initiating chemotherapy.
Researchers from the University of Bristol, however, have found that
over 66% of genus Cancer patients remained uninformed and did not receive
information about the survival benefits of palliative chemotherapy.
They assessed the cases of 37 patients - with colorectal, non-small
cell lung, or pancreatic cancer - at a big teaching infirmary or a
district general hospital in the south west of England. All of the
patients had advanced cancer, and permitted digital recording of their
consultations with oncologists. In order to analyze how survival put on
was discussed when patients were offered palliative chemotherapy, the
researchers utilized data from ASPECTS - a study of patients' of
experiences treatments. Before the patient met with the oncologist, a
researcher interviewed the patient. The researcher then recorded the
consultation with the health professional and followed-up one more than time
with the patient role within the following weeks.
The investigators found that physicians were consistent in informing
patients that they were past the point of a cure and one was not being
sought for them. However, there was considerable variance in how much
information about survival benefits from palliative chemotherapy was
tending. Some
patients received numerical data ("about little Joe weeks") while other
standard an idea of timescale ("a few months extra"), vague references
("buy you some time"), or nix at all. Of the 37 patients, six were
provided with numerical information about the treatment's survival gains. Most
of the consultations, 26 of 37, resulted in a vague discussion of
natural selection benefits or in no discussion at all.
It is possible, according to the researchers, that the "intrusiveness
of unfavorable numbers," such as the turn of months or weeks left to
live, undermines a doctor's relationship with her patient and
engenders a negative state. "Giving comprehensible and appropriate
information about survival benefit is extremely difficult. In addition,
the hesitancy to inform patients of the limited survival advance of
alleviator chemotherapy may be motivated by a desire to 'protect'
patients from tough news," write the authors. "However, the reluctance to
address these difficulties and sensitivities may be hampering patients'
power to make informed decisions about their future treatment."
The researchers intimate that oncologists and genus Cancer teams should
sensitively communicate enough data that can help a patient construct
an informed, realistic decision. In addition, they advocate training
for oncologists to help them better pass along survival information to
patients.
What oncologists tell patients about endurance benefits of
palliative chemotherapy and implications for informed consent:
qualitative study
Suzanne Audrey, Julian Abel, Jane M Blazeby, Stephen Falk,
Rona Campbell
BMJ (2008). 337: a752.
doi:10.1136/bmj.a752
Click
Here to View Journal Web Site
Written by: Peter M Crosta
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More info
- Novel Structure Proteins Could Play A Role In Apoptosis
- Preregistration Trainee Pharmacist Training Programme 2008/2009 - National Pharmacy Association, UK
- CMS Allocating $49M To High-Risk Health Insurance Pools In 31 States
- ‘It Makes Me Crazy’: Woman Can’t Forget
- Swiss HIV/AIDS Statement Could Have Serious Ramifications
Dhol Foundation
Artist: Dhol Foundation
Genre(s):
New Age
Discography:
Big Drum: Small World
Year: 2001
Tracks: 12
The multi-membered Dhol Foundation (named later on a North Indian membranophone made from a heavy wooden
Subscribe to:
Posts (Atom)